Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down - What's Next?

Key Points

• Shionogi & Co., Ltd. Unsponsored ADR shares experienced a gap down opening at $8.76, having closed at $9.05 the previous day, representing a decline of 1.2%.
• The company's earnings per share for the last quarter was reported at $0.16, surpassing analysts' expectations of $0.14, despite revenue falling short of estimates at $672.90 million.
• Shionogi holds a market cap of $15.21 billion with strong liquidity ratios, including a quick ratio of 6.13 and a current ratio of 6.63.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $9.05, but opened at $8.76. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $8.96, with a volume of 250 shares changing hands.

Shionogi & Co., Ltd. Unsponsored ADR Stock Down 1.2%

The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.13 and a current ratio of 6.63. The stock has a market cap of $15.21 billion, a P/E ratio of 15.29, a P/E/G ratio of 2.03 and a beta of 0.20. The stock's fifty day simple moving average is $8.67 and its 200-day simple moving average is $8.27.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last posted its quarterly earnings data on Monday, July 28th. The company reported $0.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.02. The business had revenue of $672.90 million during the quarter, compared to the consensus estimate of $719.55 million. As a group, research analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 earnings per share for the current fiscal year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.